Platelet Integrin αIIbβ3 Inhibitor Rescues Progression of Apoptosis in Human Platelets

Jie Zhu1, Qinghang Wang1, Yumei Nie1

  • 1Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (mainland).

Insights

Tirofiban, a platelet integrin inhibitor, significantly reduces apoptosis markers like mitochondrial depolarization and reactive oxygen species in thrombin-stimulated platelets. This suggests tirofiban may act as an apoptosis inhibitor in platelets with potential clinical applications.

Area of Science:

  • Hematology
  • Cell Biology
  • Pharmacology

Background:

  • Apoptosis is crucial in platelet physiology.
  • Platelet integrin αIIbβ3 plays a role in platelet activation and apoptosis.
  • Tirofiban is an inhibitor of platelet integrin αIIbβ3.

Purpose of the Study:

  • To investigate the effect of tirofiban on platelet apoptosis.
  • To assess tirofiban's impact on mitochondrial membrane potential (ΔΨm), phosphatidylserine (PS) exposure, and reactive oxygen species (ROS) generation.
  • To determine if tirofiban inhibits thrombin-induced platelet apoptosis.

Main Methods:

  • Washed human platelets were used.
  • Platelets were pretreated with tirofiban or vehicle, then stimulated with thrombin.
  • Flow cytometry was employed to measure ΔΨm, PS exposure, and ROS production at 6 and 24 hours.

Main Results:

  • Thrombin stimulation significantly induced ΔΨm depolarization, PS exposure, and ROS production in vehicle-treated platelets.
  • Tirofiban treatment significantly attenuated these apoptotic markers compared to thrombin-stimulated platelets.
  • Tirofiban demonstrated a dose-dependent recovery of ΔΨm, reduced PS exposure, and decreased ROS production.

Conclusions:

  • Tirofiban inhibits key apoptotic events in thrombin-activated platelets.
  • The αIIbβ3 inhibitor effectively reduces mitochondrial dysfunction, PS externalization, and ROS generation.
  • Tirofiban shows potential as a clinical agent to inhibit platelet apoptosis.

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.3K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
486
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.4K